Bryan Johnson Says He Has ‘Been Thinking Things Over’ and Now Wonders Whether His Multimillion-Dollar Quest to Defeat Aging Has Gone 'Too Far'
Bryan Johnson, the tech entrepreneur behind the extreme Blueprint “Don’t Die” longevity protocol, posted on Wednesday that he’s wondering whether he’s taken his anti-aging efforts too far.
Johnson Questions His Extreme Longevity Pursuit
Johnson appeared to poke fun at his anti-aging campaign, writing on X, "been thinking things over and wonder if i’ve taken this whole longevity thing too far."
The 48-year-old did not say he was abandoning the project. Johnson has spent years turning his body into a tracked experiment involving a strict diet, exercise and sleep, testing, supplements and experimental treatments.
Biological Age Claims Face Scientific Limits
Johnson claims the program has produced measurements associated with much younger people. Those comparisons do not establish that he has reversed aging or extended his lifespan. The National Institute on Aging says researchers are still working to identify dependable measures of biological aging and whether interventions that change biomarkers improve health or longevity.
His comment arrived weeks after he disclosed an autoimmune gastritis diagnosis, a chronic condition that can damage the stomach lining and develop silently. Northeastern University researcher Ram Hariharan called Johnson "the most measured human alive," yet said the illness remained hidden for years, illustrating the limits of intensive self-tracking.
Experimental Treatments Draw Continued Medical Skepticism
Johnson has expanded his ambitions over the years. He previously said artificial intelligence and biotechnology could make immortality a "reasonable target" by 2039, while acknowledging experimental therapies carry risks. He also launched Immortals, a $1 million-a-year program offering three customers continuous monitoring, a concierge team, AI guidance and access to his protocol.
The effort follows other controversial experiments. Johnson tried plasma from his teenage son but stopped after reporting no benefit. The Food and Drug Administration says "young plasma" has not been approved to prevent aging and that no well-controlled studies demonstrate such a benefit.
Johnson has sometimes shown more restraint than his marketing suggests. He rejected claims that Ozempic reverses aging, saying, "Data is not there yet to call Ozempic as anti-aging therapy."
A 2025 review in an NIH-hosted journal similarly warned that epigenetic clocks do not yet meet clinical standards for accuracy when used to guide individual health decisions.
Image via Shutterstock